Sign up
Pharma Capital

ANGLE building the evidence base for breakthrough cancer detection system

Undoubtedly the highlight was the successful completion of US and European studies evaluating over 400 patients using the company’s Parsortix system
"Cancer" in bold
The firm's device will help scientist wage the war against cancer

ANGLE PLC (LONAGL, OTCQX: ANPCY), pioneer of a liquid biopsy that helps detect the early signs of cancer, said it had made significant progress in commercialising its breakthrough technology as it provided a review of the year just gone.

Undoubtedly the highlight was the successful completion US and European studies evaluating over 400 patients using the company’s Parsortix system to detect ovarian cancer in women with a high-risk pelvic mass.

READ: ANGLE hails results from landmark ovarian cancer study which underlines potential of its liquid biopsy

WATCH: Boss on ovarian cancer study 

“Following optimisation of the Parsortix-based pelvic mass assay, the company will validate the assay in a further, appropriately powered clinical validation study, with the goal of achieving regulatory clearance and subsequent commercialisation of this assay in Europe and the US,” said chairman Garth Selvey.

Elsewhere, a Barts Cancer Institute study into prostate cancer yielded some potentially important results using the ANGLE technology to assess patient survival.

Gaining traction

The company’s strategy to deploy the Parsortix system with key opinion leaders in the research field as a prelude to full commercialisation appears to be gaining some traction. Currently there are 145 units deployed – up from 85 a year ago – with over 30,000 blood separations completed.

It is interesting to see the Cancer Research UK Manchester Institute using the device routinely for clinical studies.

“With its differentiated competitive position, the growing body of clinical evidence and increasing research use, ANGLE is consolidating its position as a leading player in liquid biopsy; a potential multi-billion dollar market that is expected to revolutionise cancer care,” said Selvey.

Clinical trial 

Looking ahead, a clinical study of the firm’s technology in metastatic breast cancer is expected to yield results in the first half of next year.

Its primary goal is to generate data that will support a submission to the US Food & Drug Administration for use of the Parsortix system in harvesting cancer cells from metastatic breast cancer patients.

ANGLE was lossmaking for the year ended April – to the tune of around £6.4mln – which is not uncommon for a company at this formative stage of commercial development.

Revenues increased by £100,000 to £500,000, and more importantly it was sitting with £5.5mln on the balance sheet as at the period-end.

Why Invest In ANGLE plc? Read More Here

Register here to be notified of future AGL Company articles
View full AGL profile View Profile
View All

Related Articles

© biotech Capital 2018

Biotech Capital, a subsidiary of Proactive Investors, acts as the vanguard for listed biotech companies to interact with institutional and highly capitalised investors.
Headquartered in London, Biotech Capital is led by a team of Europe's leading analysts and journalists, publishing daily content, covering all key movements in the Biotechnology market.